MX2020003748A - Vectores adenovirales con dos casetes de expresion que codifican proteinas antigenicas del vsr o fragmentos de las mismas. - Google Patents

Vectores adenovirales con dos casetes de expresion que codifican proteinas antigenicas del vsr o fragmentos de las mismas.

Info

Publication number
MX2020003748A
MX2020003748A MX2020003748A MX2020003748A MX2020003748A MX 2020003748 A MX2020003748 A MX 2020003748A MX 2020003748 A MX2020003748 A MX 2020003748A MX 2020003748 A MX2020003748 A MX 2020003748A MX 2020003748 A MX2020003748 A MX 2020003748A
Authority
MX
Mexico
Prior art keywords
fragments
expression cassettes
adenoviral vectors
antigenic proteins
cassettes encoding
Prior art date
Application number
MX2020003748A
Other languages
English (en)
Inventor
Stefano Colloca
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of MX2020003748A publication Critical patent/MX2020003748A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Un vector adenoviral que comprende dos casetes de expresión, en donde cada casete de expresión comprende un transgen y un promotor , y en donde cada transgen codifica una proteína antigénica de VSR o un fragmento de la misma.
MX2020003748A 2017-10-16 2018-10-16 Vectores adenovirales con dos casetes de expresion que codifican proteinas antigenicas del vsr o fragmentos de las mismas. MX2020003748A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762572951P 2017-10-16 2017-10-16
PCT/EP2018/078212 WO2019076882A1 (en) 2017-10-16 2018-10-16 ADENOVIRAL VECTORS COMPRISING TWO EXPRESSION CASSETTES ENCODING RSV ANTIGENIC PROTEINS OR FRAGMENTS THEREOF

Publications (1)

Publication Number Publication Date
MX2020003748A true MX2020003748A (es) 2020-11-06

Family

ID=63896162

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003748A MX2020003748A (es) 2017-10-16 2018-10-16 Vectores adenovirales con dos casetes de expresion que codifican proteinas antigenicas del vsr o fragmentos de las mismas.

Country Status (8)

Country Link
US (1) US11859199B2 (es)
EP (1) EP3697919A1 (es)
JP (1) JP2020537526A (es)
CN (1) CN111527213A (es)
BR (1) BR112020007008A2 (es)
CA (1) CA3079048A1 (es)
MX (1) MX2020003748A (es)
WO (1) WO2019076882A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113897388B (zh) * 2020-07-06 2024-05-31 嘉兴安宇生物科技有限公司 一种新型黑猩猩腺病毒载体及其构建方法和应用
KR102399308B1 (ko) * 2020-11-10 2022-05-20 주식회사 비엘 코로나바이러스의 스파이크 단백질 및 뉴클레오캡시드 단백질을 동시발현하는 복제불능 아데노바이러스를 이용한 코로나바이러스 백신
WO2022102894A1 (ko) * 2020-11-10 2022-05-19 주식회사 바이오리더스 코로나바이러스의 스파이크 단백질 및 뉴클레오캡시드 단백질을 동시발현하는 복제불능 아데노바이러스를 이용한 코로나바이러스 백신
KR20230157180A (ko) * 2022-05-09 2023-11-16 주식회사 비엘 코로나바이러스의 스파이크 단백질, 뉴클레오캡시드 단백질 및 PgsA 단백질을 동시발현하는 복제불능 아데노바이러스를 이용한 코로나바이러스 백신

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005015728A1 (de) 2005-04-06 2006-10-12 Robert Bosch Gmbh Verbindungsvorrichtung für einen Antrieb sowie Verfahren zur Herstellung einer Verbindungsvorrichtung
US8883493B2 (en) * 2007-01-30 2014-11-11 Cedars-Sinai Medical Center Adenoviral vector comprising herpes simplex virus type 1 thymidine kinase and a transgene for increasing the expression of the transgene
WO2008114149A2 (en) 2007-03-21 2008-09-25 Id Biomedical Corporation Of Quebec Chimeric antigens
ES2898235T3 (es) 2009-02-02 2022-03-04 Glaxosmithkline Biologicals Sa Secuencias de aminoácidos y de ácidos nucleicos de adenovirus de simio, vectores que las contienen, y sus usos
WO2012021730A2 (en) 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine
WO2012089231A1 (en) 2010-12-30 2012-07-05 Okairòs Ag Paramyxovirus vaccines
EP2678433B1 (en) 2011-02-22 2017-05-03 California Institute of Technology Delivery of proteins using adeno-associated virus (aav) vectors
CN104797251A (zh) 2012-11-16 2015-07-22 阿勒根公司 用前列腺素ep4激动剂组合进行皮肤创伤治愈和疤痕减少
CA2951430A1 (en) 2014-06-13 2015-12-17 Glaxosmithkline Biologicals Sa Immunogenic combinations
CN107921118B (zh) 2015-06-12 2022-11-08 葛兰素史密丝克莱恩生物有限公司 腺病毒多核苷酸和多肽
GB201513176D0 (en) 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response

Also Published As

Publication number Publication date
CA3079048A1 (en) 2019-04-25
CN111527213A (zh) 2020-08-11
US11859199B2 (en) 2024-01-02
BR112020007008A2 (pt) 2020-11-17
WO2019076882A1 (en) 2019-04-25
US20210189422A1 (en) 2021-06-24
EP3697919A1 (en) 2020-08-26
JP2020537526A (ja) 2020-12-24

Similar Documents

Publication Publication Date Title
MX2020003748A (es) Vectores adenovirales con dos casetes de expresion que codifican proteinas antigenicas del vsr o fragmentos de las mismas.
CY1124213T1 (el) Διαβιβαστες aav που περιεχουν γονιδιο κωδικοποιησης του παραγοντα viii
CR20170139A (es) Proteínas de fusión, bacterias recombinantes y métodos de uso de las bacterias recombinantes
CY1122833T1 (el) Ογκολυτικος αδενοϊος που κωδικοποιει μια πρωτεϊνη β7
PH12019500068A1 (en) Novel adeno-associated virus capsid proteins
CY1124921T1 (el) Μεθοδοι για την εκχυλιση και τον καθαρισμο μη μετουσιωμενων πρωτεϊνων
WO2016168728A3 (en) Recombinant promoters and vectors for protein expression in liver and use thereof
MY189425A (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
MX2021000047A (es) Proteina de fusion variante pd1-4-1bbl y procedimientos de uso de la misma.
BR112021020023A2 (pt) Ligantes de conjugação melhorados
EA202091054A1 (ru) Слитые молекулы на основе антитела против pd-l1 и ил-7
MX2021000263A (es) Proteina de fusion variante sirpalfa-4-1bbl y procedimientos de uso de la misma.
CY1122644T1 (el) Πρωτεϊνες συντηξης tatk-cdkl5, συνθεσεις, φαρμακοτεχνικες μορφες και η χρηση αυτων
MX2022016105A (es) Vacuna autoamplificadora de arn del sars-cov-2.
MX2018012550A (es) Composiciones y metodos para la deteccion de proteinas de celulas huesped.
CL2017000200A1 (es) Célula huésped mejorada para producir proteinas
EP3912989A4 (en) PENETRATING PEPTIDE BASED ON THE M2 PROTEIN OF THE INFLUENZA VIRUS
PH12020552222A1 (en) Immunodominant proteins and fragments in multiple sclerosis
EP4054343C0 (en) EXTENDED WHEY PROTEIN HYDROLYSATE WITH TOLERogenic PEPTIDES
CY1124079T1 (el) Αποτελεσματικη επιλεκτικοτητα των ανασυνδυασμενων πρωτεϊνων
EP3956439A4 (en) RECOMBINANT CLASSICAL SWINE FEVER VIRUS
WO2020022898A3 (en) Off-the-shelf cancer vaccines
PE20200487A1 (es) Proteinas de union al antigeno anti-jagged1
RU2015102383A (ru) ЭКСПРЕССИРУЮЩИЕ ПЛАЗМИДНЫЕ ВЕКТОРЫ pET32a(+)ASFV/p30e1 И pET32b(+)ASFV/p30e2 ДЛЯ СИНТЕЗА РЕКОМБИНАНТНЫХ БЕЛКОВ, СОСТОЯЩИХ ИЗ ФРАГМЕНТА p30 ВИРУСА АФРИКАНСКОЙ ЧУМЫ СВИНЕЙ, ТИОРЕДОКСИНА И ПОЛИГИСТИДИНОВЫХ УЧАСТКОВ
MX2023003934A (es) Antigenos de consenso de filovirus, construcciones de acido nucleico y vacunas realizadas a partir de estos, y metodos para utilizarlos.